Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 26 entries
Sorted by: Best Match Show Resources per page
[Gliptines: a new fashion?].

La Revue du praticien

Scheen AJ.
PMID: 23687746
Rev Prat. 2013 Mar;63(3):304-5.

No abstract available.

Cite
Scheen AJ. Les gliptines, une nouvelle mode? [Gliptines: a new fashion?]. Rev Prat. 2013;63(3):304-5
Scheen, A. J. (2013). Les gliptines, une nouvelle mode? [Gliptines: a new fashion?]. La Revue du praticien, 63(3), 304-5.
Scheen, André J. "Les gliptines, une nouvelle mode?" [Gliptines: a new fashion?]. La Revue du praticien vol. 63,3 (2013): 304-5.
Scheen AJ. Les gliptines, une nouvelle mode? [Gliptines: a new fashion?]. Rev Prat. 2013 Mar;63(3):304-5. French. PMID: 23687746.
Copy Download .nbib Format: NLM
Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis.

Diabetes/metabolism research and reviews

Overbeek JA, Bakker M, van der Heijden AAWA, van Herk-Sukel MPP, Herings RMC, Nijpels G.
PMID: 29573125
Diabetes Metab Res Rev. 2018 Jul;34(5):e3004. doi: 10.1002/dmrr.3004. Epub 2018 Apr 26.

The long-term impact of dipeptidyl peptidase-4 (DPP-4) inhibition is unknown, and there are concerns about the influence of DPP-4 inhibition on carcinogenesis of the pancreas and thyroid. As DPP-4 is a rather unselective enzyme present in many tissues, we...

Cite
Overbeek JA, Bakker M, van der Heijden AAWA, et al. Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2018;34(5):e3004doi: 10.1002/dmrr.3004.
Overbeek, J. A., Bakker, M., van der Heijden, A. A. W. A., van Herk-Sukel, M. P. P., Herings, R. M. C., & Nijpels, G. (2018). Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis. Diabetes/metabolism research and reviews, 34(5), e3004. https://doi.org/10.1002/dmrr.3004
Overbeek, Jetty A, et al. "Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis." Diabetes/metabolism research and reviews vol. 34,5 (2018): e3004. doi: https://doi.org/10.1002/dmrr.3004
Overbeek JA, Bakker M, van der Heijden AAWA, van Herk-Sukel MPP, Herings RMC, Nijpels G. Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2018 Jul;34(5):e3004. doi: 10.1002/dmrr.3004. Epub 2018 Apr 26. PMID: 29573125.
Copy Download .nbib Format: NLM
A high-throughput screening assay for dipeptidyl peptidase-IV inhibitors using human plasma.

Analytical methods : advancing methods and applications

Zhang J, Qian XK, Song PF, Li XD, Wang AQ, Huo H, Yao JC, Zhang GM, Zou LW.
PMID: 34036983
Anal Methods. 2021 Jun 24;13(24):2671-2678. doi: 10.1039/d1ay00415h.

Dipeptidyl peptidase-IV (DPP-IV) plays a critical role in glucose metabolism and has become an important target for type 2 diabetes mellitus. We previously reported a two-photon fluorescent probe glycyl-prolyl-N-butyl-4-amino-1,8-naphthalimide (GP-BAN) for DPP-IV detection with high specificity and sensitivity. In...

Cite
Zhang J, Qian XK, Song PF, et al. A high-throughput screening assay for dipeptidyl peptidase-IV inhibitors using human plasma. Anal Methods. 2021;13(24):2671-2678doi: 10.1039/d1ay00415h.
Zhang, J., Qian, X. K., Song, P. F., Li, X. D., Wang, A. Q., Huo, H., Yao, J. C., Zhang, G. M., & Zou, L. W. (2021). A high-throughput screening assay for dipeptidyl peptidase-IV inhibitors using human plasma. Analytical methods : advancing methods and applications, 13(24), 2671-2678. https://doi.org/10.1039/d1ay00415h
Zhang, Jing, et al. "A high-throughput screening assay for dipeptidyl peptidase-IV inhibitors using human plasma." Analytical methods : advancing methods and applications vol. 13,24 (2021): 2671-2678. doi: https://doi.org/10.1039/d1ay00415h
Zhang J, Qian XK, Song PF, Li XD, Wang AQ, Huo H, Yao JC, Zhang GM, Zou LW. A high-throughput screening assay for dipeptidyl peptidase-IV inhibitors using human plasma. Anal Methods. 2021 Jun 24;13(24):2671-2678. doi: 10.1039/d1ay00415h. PMID: 34036983.
Copy Download .nbib Format: NLM
DPP-4 inhibitors for the treatment of type 2 diabetes: a methodology overview of systematic reviews.

Acta diabetologica

Ling J, Ge L, Zhang DH, Wang YF, Xie ZL, Tian JH, Xiao XH, Yang KH.
PMID: 29858660
Acta Diabetol. 2019 Jan;56(1):7-27. doi: 10.1007/s00592-018-1164-5. Epub 2018 Jun 01.

AIMS: To evaluate the methodological quality of systematic reviews (SRs), and summarize evidence of important outcomes from dipeptidyl peptidase-4 inhibitors (DPP4-I) in treating type 2 diabetes mellitus (T2DM).METHODS: We included SRs of DPP4-I for the treatment of T2DM until...

Cite
Ling J, Ge L, Zhang DH, et al. DPP-4 inhibitors for the treatment of type 2 diabetes: a methodology overview of systematic reviews. Acta Diabetol. 2018;56(1):7-27doi: 10.1007/s00592-018-1164-5.
Ling, J., Ge, L., Zhang, D. H., Wang, Y. F., Xie, Z. L., Tian, J. H., Xiao, X. H., & Yang, K. H. (2019). DPP-4 inhibitors for the treatment of type 2 diabetes: a methodology overview of systematic reviews. Acta diabetologica, 56(1), 7-27. https://doi.org/10.1007/s00592-018-1164-5
Ling, Juan, et al. "DPP-4 inhibitors for the treatment of type 2 diabetes: a methodology overview of systematic reviews." Acta diabetologica vol. 56,1 (2019): 7-27. doi: https://doi.org/10.1007/s00592-018-1164-5
Ling J, Ge L, Zhang DH, Wang YF, Xie ZL, Tian JH, Xiao XH, Yang KH. DPP-4 inhibitors for the treatment of type 2 diabetes: a methodology overview of systematic reviews. Acta Diabetol. 2019 Jan;56(1):7-27. doi: 10.1007/s00592-018-1164-5. Epub 2018 Jun 01. PMID: 29858660.
Copy Download .nbib Format: NLM
[The expectation for DPP-4 inhibitors on future treatment of type 2 diabetes mellitus].

Nihon rinsho. Japanese journal of clinical medicine

Kawamori R.
PMID: 21838055
Nihon Rinsho. 2011 Aug;69(8):1515-9.

Since onset of type 2 diabetes mellitus is triggered by various pathophysiological defects, differently-acting drugs might be required to treat type 2 diabetes effectively. The ultimate goals of diabetes treatment are; to maintain and utilize the endogenous insulin secretion...

Cite
Kawamori R. [The expectation for DPP-4 inhibitors on future treatment of type 2 diabetes mellitus]. Nihon Rinsho. 2011;69(8):1515-9
Kawamori, R. (2011). [The expectation for DPP-4 inhibitors on future treatment of type 2 diabetes mellitus]. Nihon rinsho. Japanese journal of clinical medicine, 69(8), 1515-9.
Kawamori, Ryuzo. "[The expectation for DPP-4 inhibitors on future treatment of type 2 diabetes mellitus]." Nihon rinsho. Japanese journal of clinical medicine vol. 69,8 (2011): 1515-9.
Kawamori R. [The expectation for DPP-4 inhibitors on future treatment of type 2 diabetes mellitus]. Nihon Rinsho. 2011 Aug;69(8):1515-9. Japanese. PMID: 21838055.
Copy Download .nbib Format: NLM
Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948-1957.

Diabetes care

Singh AK, Singh R, Khunti K.
PMID: 33218984
Diabetes Care. 2020 Dec;43(12):e200-e201. doi: 10.2337/dc20-1950.

No abstract available.

Cite
Singh AK, Singh R, Khunti K. Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948-1957. Diabetes Care. 2020;43(12):e200-e201doi: 10.2337/dc20-1950.
Singh, A. K., Singh, R., & Khunti, K. (2020). Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948-1957. Diabetes care, 43(12), e200-e201. https://doi.org/10.2337/dc20-1950
Singh, Awadhesh Kumar, et al. "Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948-1957." Diabetes care vol. 43,12 (2020): e200-e201. doi: https://doi.org/10.2337/dc20-1950
Singh AK, Singh R, Khunti K. Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948-1957. Diabetes Care. 2020 Dec;43(12):e200-e201. doi: 10.2337/dc20-1950. PMID: 33218984.
Copy Download .nbib Format: NLM
Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes.

PharmacoEconomics

Geng J, Yu H, Mao Y, Zhang P, Chen Y.
PMID: 25736235
Pharmacoeconomics. 2015 Jun;33(6):581-97. doi: 10.1007/s40273-015-0266-y.

BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of antidiabetic drugs used for treating type 2 diabetes mellitus. While many studies have reported on the cost-effectiveness of DPP-4 inhibitors for treating type 2 diabetes, a systematic review of...

Cite
Geng J, Yu H, Mao Y, et al. Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Pharmacoeconomics. 2015;33(6):581-97doi: 10.1007/s40273-015-0266-y.
Geng, J., Yu, H., Mao, Y., Zhang, P., & Chen, Y. (2015). Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes. PharmacoEconomics, 33(6), 581-97. https://doi.org/10.1007/s40273-015-0266-y
Geng, Jinsong, et al. "Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes." PharmacoEconomics vol. 33,6 (2015): 581-97. doi: https://doi.org/10.1007/s40273-015-0266-y
Geng J, Yu H, Mao Y, Zhang P, Chen Y. Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Pharmacoeconomics. 2015 Jun;33(6):581-97. doi: 10.1007/s40273-015-0266-y. PMID: 25736235.
Copy Download .nbib Format: NLM
Dipeptidyl peptidase-4 inhibitors and their potential role in the management of atherosclerosis--A review.

Diabetes & metabolic syndrome

Singh TP, Vangaveti VN, Malabu UH.
PMID: 26067782
Diabetes Metab Syndr. 2015 Oct-Dec;9(4):223-9. doi: 10.1016/j.dsx.2015.04.005. Epub 2015 Jun 02.

BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a relatively new class of anti-diabetic drugs that have therapeutic potential in the management of atherosclerosis. Of the numerous DPP-4 inhibitors in clinical practice no studies have been conducted to compare their anti-atherosclerotic...

Cite
Singh TP, Vangaveti VN, Malabu UH. Dipeptidyl peptidase-4 inhibitors and their potential role in the management of atherosclerosis--A review. Diabetes Metab Syndr. 2015;9(4):223-9doi: 10.1016/j.dsx.2015.04.005.
Singh, T. P., Vangaveti, V. N., & Malabu, U. H. (2015). Dipeptidyl peptidase-4 inhibitors and their potential role in the management of atherosclerosis--A review. Diabetes & metabolic syndrome, 9(4), 223-9. https://doi.org/10.1016/j.dsx.2015.04.005
Singh, Tejas P, et al. "Dipeptidyl peptidase-4 inhibitors and their potential role in the management of atherosclerosis--A review." Diabetes & metabolic syndrome vol. 9,4 (2015): 223-9. doi: https://doi.org/10.1016/j.dsx.2015.04.005
Singh TP, Vangaveti VN, Malabu UH. Dipeptidyl peptidase-4 inhibitors and their potential role in the management of atherosclerosis--A review. Diabetes Metab Syndr. 2015 Oct-Dec;9(4):223-9. doi: 10.1016/j.dsx.2015.04.005. Epub 2015 Jun 02. PMID: 26067782.
Copy Download .nbib Format: NLM
Incretin-based drugs were not linked to HF hospitalization compared with other oral antidiabetic drug combinations.

Annals of internal medicine

Smith DA.
PMID: 27429313
Ann Intern Med. 2016 Jul 19;165(2):JC11. doi: 10.7326/ACPJC-2016-165-2-011.

No abstract available.

Cite
Smith DA. Incretin-based drugs were not linked to HF hospitalization compared with other oral antidiabetic drug combinations. Ann Intern Med. 2016;165(2):JC11doi: 10.7326/ACPJC-2016-165-2-011.
Smith, D. A. (2016). Incretin-based drugs were not linked to HF hospitalization compared with other oral antidiabetic drug combinations. Annals of internal medicine, 165(2), JC11. https://doi.org/10.7326/ACPJC-2016-165-2-011
Smith, Donald A. "Incretin-based drugs were not linked to HF hospitalization compared with other oral antidiabetic drug combinations." Annals of internal medicine vol. 165,2 (2016): JC11. doi: https://doi.org/10.7326/ACPJC-2016-165-2-011
Smith DA. Incretin-based drugs were not linked to HF hospitalization compared with other oral antidiabetic drug combinations. Ann Intern Med. 2016 Jul 19;165(2):JC11. doi: 10.7326/ACPJC-2016-165-2-011. PMID: 27429313.
Copy Download .nbib Format: NLM
An interview with the author of this issue's Editorial.

Journal of diabetes

Bloomgarden Z.
PMID: 23134413
J Diabetes. 2012 Dec;4(4):318. doi: 10.1111/1753-0407.12012.

No abstract available.

Cite
Bloomgarden Z. An interview with the author of this issue's Editorial. J Diabetes. 2012;4(4):318doi: 10.1111/1753-0407.12012.
Bloomgarden, Z. (2012). An interview with the author of this issue's Editorial. Journal of diabetes, 4(4), 318. https://doi.org/10.1111/1753-0407.12012
Bloomgarden, Zachary. "An interview with the author of this issue's Editorial." Journal of diabetes vol. 4,4 (2012): 318. doi: https://doi.org/10.1111/1753-0407.12012
Bloomgarden Z. An interview with the author of this issue's Editorial. J Diabetes. 2012 Dec;4(4):318. doi: 10.1111/1753-0407.12012. PMID: 23134413.
Copy Download .nbib Format: NLM
[Coming into focus: dipeptidyl peptidase 4 inhibitors (gliptins)].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete

Wedi B.
PMID: 31041479
Hautarzt. 2019 May;70(5):388-391. doi: 10.1007/s00105-019-4400-1.

No abstract available.

Cite
Wedi B. Dipeptidylpeptidase-4-Inhibitoren (Gliptine) geraten in den Fokus. [Coming into focus: dipeptidyl peptidase 4 inhibitors (gliptins)]. Hautarzt. 2019;70(5):388-391doi: 10.1007/s00105-019-4400-1.
Wedi, B. (2019). Dipeptidylpeptidase-4-Inhibitoren (Gliptine) geraten in den Fokus. [Coming into focus: dipeptidyl peptidase 4 inhibitors (gliptins)]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 70(5), 388-391. https://doi.org/10.1007/s00105-019-4400-1
Wedi, Bettina. "Dipeptidylpeptidase-4-Inhibitoren (Gliptine) geraten in den Fokus." [Coming into focus: dipeptidyl peptidase 4 inhibitors (gliptins)]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete vol. 70,5 (2019): 388-391. doi: https://doi.org/10.1007/s00105-019-4400-1
Wedi B. Dipeptidylpeptidase-4-Inhibitoren (Gliptine) geraten in den Fokus. [Coming into focus: dipeptidyl peptidase 4 inhibitors (gliptins)]. Hautarzt. 2019 May;70(5):388-391. doi: 10.1007/s00105-019-4400-1. German. PMID: 31041479.
Copy Download .nbib Format: NLM
Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.

Diabetes & metabolism

Rehman MB, Tudrej BV, Soustre J, Buisson M, Archambault P, Pouchain D, Vaillant-Roussel H, Gueyffier F, Faillie JL, Perault-Pochat MC, Cornu C, Boussageon R.
PMID: 27745828
Diabetes Metab. 2017 Feb;43(1):48-58. doi: 10.1016/j.diabet.2016.09.005. Epub 2016 Oct 10.

BACKGROUND: Guidelines for type 2 diabetes (T2D) recommend reducing HbAMETHODS: A systematic review of the literature (PubMed, Cochrane Library Central Register of Controlled Trials [CENTRAL] and https://clinicaltrials.gov), including all RCTs vs placebo published up to May 2015 and the...

Cite
Rehman MB, Tudrej BV, Soustre J, et al. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials. Diabetes Metab. 2016;43(1):48-58doi: 10.1016/j.diabet.2016.09.005.
Rehman, M. B., Tudrej, B. V., Soustre, J., Buisson, M., Archambault, P., Pouchain, D., Vaillant-Roussel, H., Gueyffier, F., Faillie, J. L., Perault-Pochat, M. C., Cornu, C., & Boussageon, R. (2017). Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials. Diabetes & metabolism, 43(1), 48-58. https://doi.org/10.1016/j.diabet.2016.09.005
Rehman, M B, et al. "Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials." Diabetes & metabolism vol. 43,1 (2017): 48-58. doi: https://doi.org/10.1016/j.diabet.2016.09.005
Rehman MB, Tudrej BV, Soustre J, Buisson M, Archambault P, Pouchain D, Vaillant-Roussel H, Gueyffier F, Faillie JL, Perault-Pochat MC, Cornu C, Boussageon R. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials. Diabetes Metab. 2017 Feb;43(1):48-58. doi: 10.1016/j.diabet.2016.09.005. Epub 2016 Oct 10. PMID: 27745828.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 26 entries